Rezolute announces fda clearance of ind application for phase 3 registrational study of rz358 for treatment of hypoglycemia due to tumor hyperinsulinism

Second rare disease program with rz358 in phase 3 development follows successful treatment of multiple patients with tumor hyperinsulinism under the company's expanded access program redwood city, calif., aug. 05, 2024 (globe newswire) -- rezolute, inc. (nasdaq: rzlt) (“rezolute” or the “company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it received u.s. food and drug administration (fda) clearance for its investigational new drug (ind) application for rz358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (hi).
RZLT Ratings Summary
RZLT Quant Ranking